Edwards Lifesciences Corporation (EW) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 1.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,203,480 shares of the medical research company’s stock after selling 101,056 shares during the period. Bank of New York Mellon Corp owned 2.46% of Edwards Lifesciences Corporation worth $568,792,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Egerton Capital UK LLP bought a new stake in shares of Edwards Lifesciences Corporation during the second quarter worth about $217,805,000. Koch Industries Inc. increased its position in shares of Edwards Lifesciences Corporation by 28,363.1% during the second quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock worth $1,386,000 after acquiring an additional 1,392,345 shares in the last quarter. Artisan Partners Limited Partnership increased its position in shares of Edwards Lifesciences Corporation by 90.6% during the second quarter. Artisan Partners Limited Partnership now owns 1,278,532 shares of the medical research company’s stock worth $151,174,000 after acquiring an additional 607,784 shares in the last quarter. Old Mutual Global Investors UK Ltd. increased its position in shares of Edwards Lifesciences Corporation by 83.0% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock worth $120,337,000 after acquiring an additional 499,436 shares in the last quarter. Finally, Harbour Capital Advisors LLC increased its position in shares of Edwards Lifesciences Corporation by 41,462.8% during the second quarter. Harbour Capital Advisors LLC now owns 412,303 shares of the medical research company’s stock worth $3,487,000 after acquiring an additional 411,311 shares in the last quarter. 82.17% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Corporation (EW) traded up $1.39 during mid-day trading on Tuesday, hitting $105.24. 1,104,700 shares of the company traded hands, compared to its average volume of 1,647,799. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.45. The company has a market cap of $22,110.00, a price-to-earnings ratio of 28.77, a P/E/G ratio of 1.86 and a beta of 0.46.

This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/edwards-lifesciences-corporation-ew-shares-sold-by-bank-of-new-york-mellon-corp/1783961.html

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. During the same period in the prior year, the business posted $0.68 EPS. Edwards Lifesciences Corporation’s revenue for the quarter was up 11.1% on a year-over-year basis. equities analysts predict that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current fiscal year.

EW has been the subject of several recent research reports. Royal Bank Of Canada reissued a “buy” rating and set a $130.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price objective for the company in a research report on Tuesday, July 18th. SunTrust Banks, Inc. upped their price objective on shares of Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a research report on Monday, July 17th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $135.00 price objective (down from $155.00) on shares of Edwards Lifesciences Corporation in a research report on Wednesday, October 25th. Seven investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $125.17.

In other Edwards Lifesciences Corporation news, VP Larry L. Wood sold 18,960 shares of the stock in a transaction on Friday, September 15th. The shares were sold at an average price of $112.58, for a total transaction of $2,134,516.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $112.15, for a total transaction of $594,395.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 139,580 shares of company stock worth $15,143,994. 2.13% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences Corporation (EW) Shares Sold by Bank of New York Mellon Corp” was originally published by Zolmax and is the property of of Zolmax. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://zolmax.com/investing/edwards-lifesciences-corporation-ew-shares-sold-by-bank-of-new-york-mellon-corp/1783961.html.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Western Asset Municipal Defined Opportunity Trust Inc.  To Go Ex-Dividend on November 22nd
Western Asset Municipal Defined Opportunity Trust Inc. To Go Ex-Dividend on November 22nd
Insider Selling: KLA-Tencor Corporation  Insider Sells $324,762.48 in Stock
Insider Selling: KLA-Tencor Corporation Insider Sells $324,762.48 in Stock
NextEra Energy, Inc.  To Go Ex-Dividend on November 22nd
NextEra Energy, Inc. To Go Ex-Dividend on November 22nd
Rayonier Inc.  Expected to Announce Quarterly Sales of $165.08 Million
Rayonier Inc. Expected to Announce Quarterly Sales of $165.08 Million
Comparing Buckle, Inc.   & Kate Spade & Co
Comparing Buckle, Inc. & Kate Spade & Co
SPDR S&P 500 ETF Trust  Holdings Reduced by First Business Financial Services Inc.
SPDR S&P 500 ETF Trust Holdings Reduced by First Business Financial Services Inc.


Leave a Reply

 
© 2006-2017 Zolmax.